Anti-H5N1 immunoglobulin - Fab'entech

Drug Profile

Anti-H5N1 immunoglobulin - Fab'entech

Alternative Names: FBF001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Fab entech
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(In volunteers) in Singapore (Parenteral, Injection)
  • 12 Oct 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype (In volunteers) in Singapore (Parenteral)
  • 01 Dec 2011 Preclinical trials in Influenza-A virus H5N1 subtype in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top